Expression of multidrug resistance-associated protein (MRP) mRNA in blast cells from acute myeloid leukemia (AML) patients

Leukemia

Volumn 10, Issue 1, 1996, Pages 48-55

  Ross, D D ^a,b   Doyle, L A ^a   Schiffer, C A ^a   Lee, E J ^a   Grant, C E ^c   Cole, S P C ^c   Deeley, R G ^c   Yang, W ^a   Tong, Y ^a  

^a UNIVERSITY OF MARYLAND GREENEBAUM CANCER CENTER   (United States)

^b BALTIMORE VA MEDICAL CENTER   (United States)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

Acute leukemia; AML; Drug resistance; Multidrug resistance; Multidrug resistance associated protein; P glycoprotein

Indexed keywords

BETA ACTIN; COMPLEMENTARY DNA; DAUNORUBICIN; GLYCOPROTEIN P; MESSENGER RNA; PROTEIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLAST CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ACCUMULATION; DRUG TRANSPORT; FEMALE; HUMAN; HUMAN CELL; MALE; MESSENGER RNA SYNTHESIS; MULTIDRUG RESISTANCE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 0030052751     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Kartner N, Ling V. Multidrug resistance in cancer. Scientific American 1989; 260: 44-51.
2. List AF, with reviews by Bates SE, Sikic BI. Multidrug resistance: clinical relevance in acute leukemia. Oncology 1993; 7: 23-38 (review article).
3. Baer MR, Bloomfield CD. Multidrug resistance in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 663-665.
4. Ross DD et al Enhancement of daunorubicin accumulation, retention, and cytotoxicity by verapamil or cyclosporin A in blast cells from patients with previously untreated acute myeloid leukemia. Blood 1993; 82: 1288-1299.
5. Cole SPC et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science 1992; 258: 1650-1654.
6. Grant CE et al. Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 1994; 54: 357-361.
7. Collins SJ, Gallo RC, Gallagher RE. Continuous growth and differentiation of human myeloid leukemia cells in culture. Nature 1977; 270: 247-249.
8. Marquardt D, McCrone S, Center MS. Mechanisms of multidrug resistance in HL60 cells: detection of resistance-associated proteins with antibodies against synthetic peptides that correspond to the deduced sequence of P-glycoprotein. Cancer Res 1990; 50: 1426-1430.
9. Bhalla K, Hindenberg A, Taub RN, Grant S. Isolation and characterization of an anthracycline-resistant human leukemic cell line. Cancer Res 1985; 45: 3657-3662.
10. Krishnamachary N, Center MS. The MRP gene associated with a non-P-glycoprotein multidrug resistance encodes a 190-kDa membrane bound glycoprotein. Cancer Res 1993; 53: 3658-3661.
11. Ross D et al. Synergistic reversal of multidrug-resistance phenotype by cyclosporin A and cremophor EL. Blood 1994; 83: 1337-1347.
12. Gralnick HR. Classification of acute leukemia. Ann Intern Med 1977; 87: 740-753.
13. Cheson BD et al. Report of the NCl-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813-819.
14. Boyum A. Separation of leukocytes from blood and bone marrow Scand J Clin Lab Invest 1968; 21: (suppl.) 97.
15. Hoof T, Riordan JR, Tummler B. Quantitation of mRNA by the kinetic polymerase chain reaction assay: a tool for monitoring P-glycoprotein expression. Anal Biochem 1991; 196: 161-169
16. Abbaszadegan MR et al. Analysis of multidrug resistance-associated protein (MRP) messenger RNA in normal and malignant hematopoietic cells. Cancer Res 1991; 54: 4676-4679.
17. Hart SM et al. Expression of the multidrug resistance-associated protein (MRP) in acute leukaemia. Leukemia 1994; 8: 2163-2168.
18. Zhao S, Rees JK, Andreef M. Multidrug resistance-associated protein (MRP) expression in multidrug resistant cell lines and leukemias. Blood 1993; 82: (suppl. 1): 258 (abstr. 1017).
19. Barrand MA et al. A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug resistant cells and its relationship to the MRP gene. J Natl Cancer Inst 1994; 86: 110-117.
20. Beck J, Gekeler V, Handgretinger R, Niethammer D. PCR gene expression analysis of multidrug resistance associated genes in primary and relapsed state leukemias: comparison of mdr1, mrp, topoisomerase IIα, topoisomerase IIβ and cyclin A mRNA levels. Proc Am Assoc Cancer Res 1994; 35: 337 (abstr. 2006).
21. Burger H et al. Expression of the multidrug-resistance associated protein (MRP) in acute and chronic leukemias. Leukemia 1994; 8: 990-997.
22. Schneider E et al. Increased expression of the multidrug resistance-associated protein gene in relapsed acute leukemia. Blood 1995; 85: 186-193.
23. Schuurhuis GJ et al. Functional multidrug resistance phenotype associated with combined overexpression of Pgp/MDR1 together with 1-β-D-arabinofuranosylcytocine sensitivity may predict clinical response in acute leukemia. Clin Cancer Res 1995; 1: 81-93.
24. Flens MJ et al. Immunohistochemical detection of the multidrug resistance-associated protein MRP in human multidrug resistant tumor cells by monoclonal antibodies. Cancer Res 1994; 54: 4557-4563.
25. Hipfner DR, Gauldie SD, Deeley RG, Cole SPC. Detection of the 190 kDa multidrug resistance protein, MRP, with monoclonal antibodies. Cancer Res 1994; 54: 5788-5792.
26. Cole SPC et al. Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 1994; 54: 5902-5910.
27. Kuiper CM et al. Functional detection of MRP overexpressing tumor cell lines using flow cytometry and laser scan microscopy. Proc Am Assoc Cancer Res 1994; 35: 348 (abstr. 2074).
28. Versantvoort CHM et al. Genistein modulates the decreased drug accumulation in non-P-glycoprotein mediated multidrug resistant tumour cells. Br J Cancer 1993; 68: 939-946.